Loading...
•
Sep 30, 2025
uniQure Q3 2025 Earnings Report
uniQure reported a wider net loss in Q3 2025 despite increased revenue, driven by higher operating expenses and non-operating charges.
Key Takeaways
Revenue grew year-over-year, but a significant rise in R&D and SG&A costs contributed to a higher net loss. Cash reserves strengthened following a major equity raise, extending the company’s runway into 2029.
Revenue rose to $3.7 million, driven primarily by increased license revenues.
Net loss widened to $80.5 million due to increased R&D and SG&A expenses.
Cash and investment securities totaled $694.2 million after a $323.7 million public offering.
AMT-130 showed statistically significant slowing in disease progression in Huntington's disease but faces regulatory uncertainties.
Revenue by Segment
Forward Guidance
uniQure expects its current cash reserves to fund operations into 2029. Clinical data updates are anticipated in 1H 2026 for AMT-260 and AMT-191, while the timing of a BLA submission for AMT-130 remains uncertain.
Positive Outlook
- Cash runway extended into 2029.
- Upcoming clinical data for AMT-260 expected in 1H 2026.
- AMT-191 data shows promising enzyme activity levels in Fabry disease patients.
- Successful completion of fourth cohort enrollment for AMT-130.
- Potential access to $125 million in additional debt financing.
Challenges Ahead
- FDA no longer supports use of external control data for AMT-130 BLA.
- AMT-130 BLA submission timing is now unclear.
- Enrollment paused for AMT-162 due to a serious adverse event.
- Increased SG&A and R&D costs leading to a widened net loss.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...